<DOC>
	<DOCNO>NCT01103024</DOCNO>
	<brief_summary>The purpose extension study provide patient complete 28-week core study opportunity receive additional 22 week continuous treatment .</brief_summary>
	<brief_title>Extension Study Assess Safety Efficacy AIN457 Patients With Active Non-infectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Patients complete entire treatment period 28week core study Patients must able understand communicate investigator comply requirement study must give write , sign , date informed consent study treatment extension study Inability unwillingness undergo repeat subcutaneous injection Inability comply study followup procedure Any medical psychiatric condition , investigator 's opinion would preclude participant adhere protocol complete study per protocol Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) Women childbearing potential ( WoCBP ) , define woman physiologically capable become pregnant , UNLESS They use simultaneously double barrier two acceptable method contraception They postmenopausal appropriate clinical profile regular menstrual bleeding least twelve ( 12 ) month prior initial dose They undergo reliable surgical sterilization least six ( 6 ) month prior initial dose Their career , lifestyle , sexual orientation precludes intercourse male partner Partners sterilize vasectomy reliable mean Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Active uveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>uveitis</keyword>
</DOC>